Extrahepatic Delivery With OligoPhore & SemaPhore, Peptide-based Nanoparticles for siRNA & mRNA Therapeutics

Time: 9:30 am
day: Day Two


  • Noncovalent polyplexes with any RNA that are highly stable in circulation and RNAase resistant
  • Extrahepatic delivery and efficacy for siRNA and mRNA polyplexes have been demonstrated in myriad disease models in vivo, including cancer, atherosclerosis, arthritis, metabolic syndrome, and bowel disease
  • Safety profiles after serial dosing in rodent models to date have been devoid of tissue and organ toxicity, complement activation, and immunological responses to polyplex components